Akcea Therapeutics, Inc. Contract with Customer, Asset, after Allowance for Credit Loss, Current
Akcea Therapeutics, Inc. had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $14.05 million as of 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2020-08-05
- 2020-06-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $14.05M.
- 2020-03-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $10.67M.
- 2019-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $10.50M.
- 2019-09-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $10.65M.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2020-06-30 | $14.05M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $10.67M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $10.50M 10-Q · filed 2020-08-05 |
| 2019-09-30 | $10.65M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $9.19M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $10.27M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $4.60M 10-K · filed 2020-03-02 |
| 2018-09-30 | $636.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $3.29M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-07 |
| 2017-12-31 | $5.41M 10-Q · filed 2018-11-06 |
| 2016-12-31 | $0.00 8-K · filed 2018-09-18 |